Defibrillators news | Breaking defibrillators news | Defibrillators

Baseball Player Opens Up About His Brush With Death

..."During those two weeks, I'm actually going to go around the fields and ask people if they would like to donate so we can get Those Experts say there's only about a 10% survival rate for sudden cardiac arrests like Michael Slatcher’s.

If you would like to help him raise money for a defibrillator, you can call Broken Arrow Youth Baseball at 455-2292.

Related Stories: 04/22/2007 11-Year-Old Ball Player Suffers Cardiac Arrest During Game Local News Woman Accused Of Dropping Drugs Outside A Prison Soldiers Getting A Sweet Delivery Community Mourns Two Teenagers Killed In Separate Motorcyle Accidents Gas Stations Along Turner Turnpike Close Oklahoma Schools Respond To Threats Campus Crime Report Released Baseball Player Opens Up About His Brush With Death Family Remembers Broken Arrow Graduate Killed in NASA Shooting Newspaper Says Gene Stipe Benefits From Train Sale To State Police Shooting Investigation More Local News E-Clips Today's Forecast With Travis MeyerBoost In Safe Room InstallationsYoung Baseball Player Safe At Home After Cardiac ArrestFriends Killed In Separate Motorcycle AccidentsMore E-Clips Slatcher suffered a cardiac arrest at a baseball game Saturday.

Michael Slatcher was hit in the chest with a bat and a ball at the same time....

Boston Scientific net falls on Guidant costs

...Boston Scientific said sales of drug-coated stents in the quarter were weaker than it expected as physicians referred fewer patients for the procedure after a widely publicized study found stents offered no advantage over medication in preventing heart attacks and death for some patients.

Sales of implantable cardioverter The results were "pretty much in line with relatively modest expectations," said Leerink Swann analyst Jason Wittes.

"Stents were so-so.

They continue to slide in line with what we would expect, given the J&J numbers." Boston Scientific competes in the stent market against Johnson & Johnson (JNJ.N), which last week reported a 27 percent drop in sales of its Cypher drug-coated stent.

Boston Scientific reported first-quarter net earnings of $120 million, or 8 cents per share, compared with $332 million, or 40 cents per share, a year ago.

The company said it had 1.5 billion shares outstanding, compared with 830 million before the Guidant deal.

Adjusted earnings were 20 cents per share, excluding special charges and amortization related to the Guidant acquisition and stock compensation expenses.

On that basis, Wall Street was expecting a profit of 19 cents per share, according to Reuters Estimates.

Net sales were $2.09 billion, up from $1.62 billion the year before.

Sales in the most recent quarter included the...

Profit at Boston Scientific Plummets 64%

......

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news